Besides, current treatments for some aggressive subtypes, such as triple-negative breast cancer (TNBC) and Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer, are limited, with poor prognosis.5, 4. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.